News Sentiment

IMRX sentiment intelligence

Immuneering Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.11 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-1.5% over one week, +22.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

Market Reaction

Balanced read

70/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend inactive 22.0% over four weeks
Fair value 19.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 36
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 10
Sahm 5
GlobeNewswire 5
simplywall.st 5
Investing.com 4
TradingView 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 16
Analyst action 5
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Sahm Direct company coverage

Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth

Immuneering (NASDAQ:IMRX) is an unprofitable company with a strong cash runway of over three years, possessing US$157m in cash against an annual burn of US$50m as of March 2026. The company has reduced its cash burn by 7% over the last year, indicating steady business development

Tone
Positive 71/100
Event
Balance sheet
Published
30 Jun 2026 15:41
Source
Sahm
TradingView Direct company coverage

Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX)

Immuneering Corporation's stock (IMRX) is currently trading at $4.53, having decreased slightly in the past 24 hours but showing a 57.29% increase over the last year. Analysts have a wide price target range for IMRX, with a maximum estimate of $30.00 and a minimum of $11.00. The

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 06:10
Source
TradingView
Investing.com Canada Direct company coverage

Immuneering CEO Zeskind buys $10,948 in stock By Investing.com

Immuneering Corp (NASDAQ:IMRX) CEO Benjamin J. Zeskind recently purchased 2,400 shares of the company's stock for a total of $10,948, bringing his direct holdings to over 2.3 million shares. This insider purchase occurs as the stock trades near $4.60, up significantly over the pa

Tone
Positive 81/100
Event
Market update
Published
25 Jun 2026 13:09
Source
Investing.com Canada
Investing.com Direct company coverage

Immuneering CEO Zeskind buys $10,948 in stock

Immuneering Corp's CEO, Benjamin J. Zeskind, purchased 2,400 shares of the company's Class A Common Stock for $10,948 on June 23, 2026. This insider transaction comes as the stock trades near $4.60, with InvestingPro analysis suggesting it is undervalued. The company also announc

Tone
Positive 71/100
Event
Market update
Published
25 Jun 2026 11:10
Source
Investing.com
Stock Titan Direct company coverage

Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading

Immuneering Corp. CEO Benjamin J. Zeskind purchased 2,400 shares of Class A Common Stock in an open-market transaction on June 23, 2026, at a weighted average price of $4.5617 per share. This transaction increases his direct holdings to 2,315,252 shares, with an additional 894,92

Tone
Positive 66/100
Event
Market update
Published
25 Jun 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade

Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, purchased 6,035 shares of Class A Common Stock on June 15, 2026, at a weighted average price of $4.15 per share. This open-market transaction increased his direct holdings to 382,531 shares. The trade was executed t

Tone
Positive 70/100
Event
Market update
Published
17 Jun 2026 04:39
Source
Stock Titan
Stock Titan Direct company coverage

New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant

Immuneering Corporation has appointed Andrew Gengos as its new Chief Financial Officer, Treasurer, and principal financial officer, effective on or before July 16, 2026. He will receive an annual base salary of $530,000, a target annual bonus of 40% of his base salary, and an opt

Tone
Positive 61/100
Event
Analyst action
Published
16 Jun 2026 08:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Immuneering Shareholders Approve Directors and Auditor at Meeting

Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, where shareholders elected Peter Feinberg and Laurie B. Keating as Class II directors and ratified RSM US LLP as the independent auditor for the 2026 fiscal year. This decision by 68.8% of outstandi

Tone
Positive 60/100
Event
Market update
Published
14 Jun 2026 21:39
Source
The Globe and Mail
Stock Titan Direct company coverage

Immuneering (IMRX) director receives 33,350 stock options at $4.12 strike

Immuneering Corp (IMRX) director Thomas J. Schall was granted 33,350 stock options at an exercise price of $4.12 per share. This compensation-related equity grant vests in equal monthly installments over one year, starting July 11, 2026, and will be fully vested by June 11, 2027,

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 15:09
Source
Stock Titan
Stock Titan Direct company coverage

Immuneering (IMRX) director Diana Hausman awarded 33,350 stock options at $4.12

Immuneering Corp director Diana Hausman was granted 33,350 stock options with an exercise price of $4.12 per share as compensation. These options will vest in equal monthly installments over one year, starting July 11, 2026, and will be fully vested by June 11, 2027, or the date

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 02:40
Source
Stock Titan
Minichart Direct company coverage

Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026

Immuneering Corporation (NASDAQ: IMRX) has filed a Form 8-K with the SEC detailing the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Key outcomes included the election of Peter Feinberg and Laurie B. Keating as Class II directors and the ratification o

Tone
Neutral 50/100
Event
Earnings
Published
12 Jun 2026 18:39
Source
Minichart
Finviz Direct company coverage

IMRX - Immuneering Corp Stock Price and Quote

This article provides a comprehensive overview of Immuneering Corp (IMRX) stock, including its latest closing price, financial metrics, valuation ratios, and stock performance. It also details recent analyst ratings with price targets and a chronological list of company news and

Tone
Positive 62/100
Event
Analyst action
Published
03 Jun 2026 02:14
Source
Finviz
Stock Titan Direct company coverage

[8-K] Immuneering Corp Reports Material Event

Immuneering Corporation announced updated Phase 2a results for its oral MEK inhibitor atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a median overall survival of 17.3 months. The company plans to initiate a pivotal Phase 3

Tone
Positive 74/100
Event
Earnings
Published
02 Jun 2026 14:39
Source
Stock Titan
Sahm Direct company coverage

Crude Oil Edges Higher; US Consumer Sentiment Falls In May

U.S. stocks showed gains on Friday, with the Dow Jones index rising more than 400 points, despite a significant drop in the University of Michigan's consumer sentiment index to a record low of 44.8 in May. Several equities experienced substantial movements, with Immuneering Corp,

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 21:39
Source
Sahm
Stock Titan Direct company coverage

Pancreatic data and cash runway into 2029 at Immuneering (NASDAQ: IMRX)

Immuneering Corporation reported a Q1 2026 net loss of $13.5 million and ended the quarter with $198.6 million in cash, projecting a cash runway into 2029. The company highlighted significant progress in its oncology pipeline, including the recruitment for its pivotal Phase 3 MAP

Tone
Neutral 50/100
Event
Earnings
Published
16 May 2026 06:09
Source
Stock Titan